Pacira BioSciences, Inc. (PCRX) Stock

About Pacira BioSciences, Inc.

Pacira BioSciences, Inc. is led by CEO Frank D. Lee, employs 788 people, headquartered in US, publicly traded since 2011.

Pacira BioSciences, Inc. (PCRX) stock trades at $36.42 with a market capitalization of $1.45B. The stock is valued at a price-to-earnings (P/E) ratio of 71.14, price-to-book of 1.47, price-to-sales of 1.32. Over the past 52 weeks the stock has ranged between $18.80 and $36.54, and currently trades at or near its 52-week high.

On profitability, Pacira BioSciences, Inc. generates a return on equity (ROE) of 2.13%, return on capital employed of 1.64%, an operating margin of 4.55%, a net profit margin of 1.96%.

Pacira BioSciences, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Pacira BioSciences, Inc. reported revenue of $276.0M rising to $726.0M, a change of +163.0% across 10 years. Compounded, revenue has grown 11.0% a year over five years, 2.9% over three, 3.6% over the last twelve months. Net profit rose to $7.0M.

Operating margin went from -11.6% in 2016 to 4.6% in 2025, a gain of 16.2 percentage points. The most recent net margin is 1.96%. On a trailing twelve-month basis to Jun '26, revenue is $746.0M and net profit $15.0M.

Borrowings rose from $109.0M to $454.0M, cash from operations was $152.0M in the latest year, positive in 10 of the last 10.

Return on equity has averaged 0.2% over five years, and was 1.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Pacira BioSciences, Inc. (PCRX) — frequently asked questions